Matthew Fitzgibbon
Overview
Explore the profile of Matthew Fitzgibbon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
867
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galeano Nino J, Wu H, LaCourse K, Srinivasan H, Fitzgibbon M, Minot S, et al.
Nat Protoc
. 2023 Oct;
18(11):3355-3389.
PMID: 37789194
Single-cell RNA sequencing (scRNAseq) technologies have been beneficial in revealing and describing cellular heterogeneity within mammalian tissues, including solid tumors. However, many of these techniques apply poly(A) selection of RNA,...
2.
Garcia N, Becerra J, McKinney B, DiMarco A, Wu F, Fitzgibbon M, et al.
bioRxiv
. 2023 Jul;
PMID: 37461590
APOBEC mutagenesis is one of the most common endogenous sources of mutations in human cancer and is a major source of genetic intratumor heterogeneity. High levels of APOBEC mutagenesis are...
3.
Veatch J, Lee S, Shasha C, Singhi N, Szeto J, Moshiri A, et al.
Cancer Cell
. 2022 Apr;
40(4):393-409.e9.
PMID: 35413271
CD4 T cells that recognize tumor antigens are required for immune checkpoint inhibitor efficacy in murine models, but their contributions in human cancer are unclear. We used single-cell RNA sequencing...
4.
Veatch J, Singhi N, Srivastava S, Szeto J, Jesernig B, Stull S, et al.
J Clin Invest
. 2021 Aug;
131(16).
PMID: 34396986
Therapeutic vaccines that augment T cell responses to tumor antigens have been limited by poor potency in clinical trials. In contrast, the transfer of T cells modified with foreign transgenes...
5.
Lim Y, Arora S, Schuster S, Corey L, Fitzgibbon M, Wladyka C, et al.
Nat Commun
. 2021 Jul;
12(1):4217.
PMID: 34244513
The functional consequences of genetic variants within 5' untranslated regions (UTRs) on a genome-wide scale are poorly understood in disease. Here we develop a high-throughput multi-layer functional genomics method called...
6.
Jackson L, Potter B, Schneider S, Fitzgibbon M, Blair K, Farah H, et al.
PLoS Pathog
. 2020 Dec;
16(12):e1008686.
PMID: 33370399
Helicobacter pylori chronically infects the stomach of approximately half of the world's population. Manifestation of clinical diseases associated with H. pylori infection, including cancer, is driven by strain properties and...
7.
Diab A, Gem H, Swanger J, Kim H, Smith K, Zou G, et al.
Proc Natl Acad Sci U S A
. 2020 Oct;
117(45):28287-28296.
PMID: 33093209
Head and neck squamous cell carcinoma (HNSCC) associated with high-risk human papilloma virus (HPV) infection is a growing clinical problem. The WEE1 kinase inhibitor AZD1775 (WEE1i) overrides cell cycle checkpoints...
8.
Veatch J, Jesernig B, Kargl J, Fitzgibbon M, Lee S, Baik C, et al.
Cancer Immunol Res
. 2019 May;
7(6):910-922.
PMID: 31043415
T cells specific for neoantigens encoded by mutated genes in cancers are increasingly recognized as mediators of tumor destruction after immune-checkpoint inhibitor therapy or adoptive cell transfer. Much of the...
9.
Veatch J, Lee S, Fitzgibbon M, Chow I, Jesernig B, Schmitt T, et al.
J Clin Invest
. 2018 Jan;
128(4):1563-1568.
PMID: 29360643
T cells specific for neoantigens encoded by mutated genes in cancers are increasingly recognized as mediators of tumor destruction after immune checkpoint inhibitor therapy or adoptive cell transfer. Unfortunately, most...
10.
Germann U, Furey B, Markland W, Hoover R, Aronov A, Roix J, et al.
Mol Cancer Ther
. 2017 Sep;
16(11):2351-2363.
PMID: 28939558
Aberrant activation of signaling through the RAS-RAF-MEK-ERK (MAPK) pathway is implicated in numerous cancers, making it an attractive therapeutic target. Although BRAF and MEK-targeted combination therapy has demonstrated significant benefit...